SCHEMBL1777369

SCHEMBL1777369

COC1C[C@@H](OCc2ccccc2)[C@H](OC(=O)c2ccccc2)[C@@H](COS(=O)(=O)c2ccc(C)cc2)O1

nearest known ligand 0.39

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
MAPT P10636 2/20 0.39
NT5E P21589 1/20 0.39
LGALS3 P17931 1/20 0.36
LGALS4 P56470 1/20 0.36
FOLH1 Q04609 1/20 0.36
FGF1 P05230 2/20 0.35
FGF2 P09038 2/20 0.35
VEGFA P15692 2/20 0.35
HPSE Q9Y251 2/20 0.35
RNASE1 P07998 1/20 0.35
CYP3A4 P08684 2/20 0.34
LMNA P02545 1/20 0.34
CA1 P00915 3/20 0.34
CA2 P00918 3/20 0.34
POLB P06746 1/20 0.34
TACR2 P21452 1/20 0.33
CA9 Q16790 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1777367 1.00 MAPT (0.39) MAPTNT5ELGALS3LGALS4FOLH1
SCHEMBL1777182 0.85 LMNA (0.36) MAPTFGF1FGF2VEGFAHPSE
SCHEMBL1777185 0.85 LMNA (0.36) MAPTFGF1FGF2VEGFAHPSE
SCHEMBL1775668 0.84 NT5E (0.47) MAPTNT5ELGALS3LGALS4FGF1
SCHEMBL1777133 0.82 NT5E (0.43) MAPTNT5ELGALS3LGALS4FOLH1
SCHEMBL1776211 0.81 NT5E (0.40) NT5ELGALS3RNASE1
SCHEMBL1776214 0.81 NT5E (0.40) NT5ELGALS3RNASE1
SCHEMBL1776213 0.81 NT5E (0.40) NT5ELGALS3RNASE1
SCHEMBL10757424 0.80 PDE4D (0.39) MAPTCYP3A4LMNACA1CA2
SCHEMBL10757415 0.80 PDE4D (0.39) MAPTCYP3A4LMNACA1CA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7943584-B2 Medicinal composition containing diabetes remedy SANKYO COMPANY, LIMITED (JP) 2011-05-17 US disclosed
EP-1589023-B1 OLIGOSACCHARIDE DERIVATIVE DAIICHI SANKYO CO LTD (JP) 2010-08-25 EP disclosed
US-7632930-B2 Oligosaccharide derivative SANKYO COMPANY LIMITED (JP) 2009-12-15 US disclosed
US-20080194495-A1 Oligosaccharide Derivative HONDA TAKESHI 2008-08-14 US disclosed
US-7361744-B2 Oligosaccharide derivative SANKYO COMPANY LIMITED (JP) 2008-04-22 US disclosed
US-20080039367-A1 Medicinal Composition Containing Diabeted Remedy SANKYO COMPANY, LIMITED (JP) 2008-02-14 US disclosed
EP-1792620-A1 MEDICINAL COMPOSITION CONTAINING DIABETES REMEDY Sankyo Company, Limited (JP) 2007-06-06 EP disclosed
US-20060025350-A1 Oligosaccharide derivative SANKYO COMPANY, LIMITED (JP) 2006-02-02 US disclosed
EP-1589023-A1 OLIGOSACCHARIDE DERIVATIVE Sankyo Company, Limited (JP) 2005-10-26 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080039367-A1 Medicinal Composition Containing Diabeted Remedy DPP4, IAPP, AMY2A MAPT 4096/4885NT5E 1662/4885LGALS3 577/4885
US-20060025350-A1 Oligosaccharide derivative MAN1B1, FUT6, MAN2A1 MAPT 4828/4885NT5E 3836/4885LGALS3 197/4885
US-20080194495-A1 Oligosaccharide Derivative MAN1B1, FUT6, MAN2A1 MAPT 4828/4885NT5E 3836/4885LGALS3 197/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.